Platelet function variability and non-genetic causes

Thrombosis and Haemostasis

Volumn 105, Issue SUPPL. 1, 2011, Pages 60-66

  Tentzeris, Ioannis ^a   Siller Matula, Jolanta ^b   Farhan, Serdar ^a   Jarai, Rudolf ^a   Wojta, Johann ^b   Huber, Kurt ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ADP receptors; Antiplatelet agents; Platelet pharmacology

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE;

BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 79960997692     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/THS11-01-0025     Document Type: Article

References (4)

1. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
3. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
4. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.